The stock of Castle Biosciences Inc (CSTL) has gone up by 0.34% for the week, with a 28.78% rise in the past month and a 27.56% rise in the past quarter. The volatility ratio for the week is 4.89%, and the volatility levels for the past 30 days are 6.54% for CSTL. The simple moving average for the past 20 days is 9.35% for CSTL’s stock, with a 34.83% simple moving average for the past 200 days.
Is It Worth Investing in Castle Biosciences Inc (NASDAQ: CSTL) Right Now?
The 36-month beta value for CSTL is at 1.01. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 5 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CSTL is 25.93M, and currently, shorts hold a 6.56% of that float. The average trading volume for CSTL on September 02, 2024 was 401.67K shares.
CSTL) stock’s latest price update
Castle Biosciences Inc (NASDAQ: CSTL)’s stock price has gone decline by -0.40 in comparison to its previous close of 29.79, however, the company has experienced a 0.34% increase in its stock price over the last five trading days. seekingalpha.com reported 2024-08-16 that Castle Biosciences is a fast-growing molecular diagnostics company with a focus on prognostic tests for cancer and mental health patients. The company inflected into net income and operating profitability in Q2 2024, driving institutional and retail interest. CSTL faces risks from the loss of its DecisionDX-SCC business and general obsolescence in the cancer prognostic testing field.
Analysts’ Opinion of CSTL
Many brokerage firms have already submitted their reports for CSTL stocks, with Guggenheim repeating the rating for CSTL by listing it as a “Buy.” The predicted price for CSTL in the upcoming period, according to Guggenheim is $25 based on the research report published on December 14, 2023 of the previous year 2023.
Scotiabank, on the other hand, stated in their research note that they expect to see CSTL reach a price target of $54. The rating they have provided for CSTL stocks is “Sector Outperform” according to the report published on January 05th, 2023.
Stephens gave a rating of “Overweight” to CSTL, setting the target price at $59 in the report published on January 07th of the previous year.
CSTL Trading at 28.53% from the 50-Day Moving Average
After a stumble in the market that brought CSTL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -2.58% of loss for the given period.
Volatility was left at 6.54%, however, over the last 30 days, the volatility rate increased by 4.89%, as shares surge +33.17% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +40.82% upper at present.
During the last 5 trading sessions, CSTL rose by +0.34%, which changed the moving average for the period of 200-days by +67.44% in comparison to the 20-day moving average, which settled at $27.50. In addition, Castle Biosciences Inc saw 37.49% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CSTL starting from MAETZOLD DEREK J, who sale 1,746 shares at the price of $30.09 back on Aug 23 ’24. After this action, MAETZOLD DEREK J now owns 8,356 shares of Castle Biosciences Inc, valued at $52,535 using the latest closing price.
MAETZOLD DEREK J, the Pres. & Chief Exec. Officer of Castle Biosciences Inc, sale 1,037 shares at $30.09 during a trade that took place back on Aug 23 ’24, which means that MAETZOLD DEREK J is holding 102,019 shares at $31,202 based on the most recent closing price.
Stock Fundamentals for CSTL
Current profitability levels for the company are sitting at:
- -0.05 for the present operating margin
- 0.79 for the gross margin
The net margin for Castle Biosciences Inc stands at -0.01. The total capital return value is set at -0.04. Equity return is now at value -0.77, with -0.68 for asset returns.
Based on Castle Biosciences Inc (CSTL), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at 4.12. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is -54.71.
Currently, EBITDA for the company is -55.65 million with net debt to EBITDA at -616.14. When we switch over and look at the enterprise to sales, we see a ratio of 2.65. The receivables turnover for the company is 6.25for trailing twelve months and the total asset turnover is 0.59. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.12.
Conclusion
In conclusion, Castle Biosciences Inc (CSTL) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
